Urothelial Carcinoma Clinical Trial Tracker — Monitor the ADC Pipeline After EV Approval

Why urothelial carcinoma trial monitoring matters

The treatment landscape for metastatic urothelial carcinoma (mUC) was transformed in 2024 when EV-302/KEYNOTE-A39 established enfortumab vedotin plus pembrolizumab (Padcev + Keytruda) as the new first-line standard, displacing platinum-based chemotherapy for eligible patients. That approval did not close the field — it opened it. The ADC hypothesis in urothelial is now validated, and multiple sponsors are attempting to compete in first-line, find footholds in second-line, or capture the FGFR3-mutant segment that remains a distinct therapeutic opportunity.

For pharma BD teams and oncology investors, key signals to track:

• ADC programs entering Phase 1/2 in urothelial — potential challengers or combination partners to EV
• Dato-DXd (datopotamab deruxtecan) Phase 2/3 by Daiichi Sankyo vs. gemcitabine+platin — the most significant ongoing trial in 1L mUC
• TROP2 ADC programs (sacituzumab govitecan by Gilead) pursuing urothelial-specific expansion
• FGFR3-targeted agents (dabogratinib by Tyra Biosciences) in upper tract urothelial carcinoma
• Novel combination strategies pairing next-gen checkpoint inhibitors or antibody combinations with established ADCs
• BCG alternatives for non-muscle-invasive bladder cancer (NMIBC) — a distinct unmet need

Current urothelial carcinoma trial activity (as of March 2026)

Based on ClinicalTrials.gov data updated daily by DataLookout:

Phase	Recruiting Trials	Key Sponsors
Phase 2/3	3	Daiichi Sankyo, Verity Pharmaceuticals
Phase 2	7	AstraZeneca, Gilead, Tyra Biosciences
Phase 1/2	4	Alentis Therapeutics, GI Innovation
Phase 1	2	Pfizer, SystImmune
Total recruiting	20	10 industry-sponsored

The industry-sponsored urothelial landscape is concentrated in later-stage programs (Phase 2 and above), reflecting the maturity of the field post-EV approval. The 10 industry trials capture both approved agent expansion (Gilead's sacituzumab govitecan, AstraZeneca/Daiichi's Dato-DXd) and novel mechanism entry (FGFR3-selective inhibitors, novel ADCs).

The urothelial carcinoma competitive landscape in 2026

The ADC race post-enfortumab vedotin

Enfortumab vedotin (EV) targets Nectin-4, a cell adhesion protein broadly expressed on urothelial tumor cells. Its approval in combination with pembrolizumab established ADC-based therapy as the new first-line backbone in mUC. The critical strategic question now facing the field: what comes next? Two major programs are testing this directly. AstraZeneca and Daiichi Sankyo are running a Phase 2 study of datopotamab deruxtecan (Dato-DXd, an anti-TROP2 ADC with a topoisomerase I inhibitor payload) as monotherapy and in combination in urothelial patients who progressed after EV — explicitly targeting the EV-refractory population. Simultaneously, Daiichi Sankyo has initiated a Phase 2/3 registrational study of Dato-DXd plus carboplatin or cisplatin versus gemcitabine plus carboplatin/cisplatin in 1L mUC. If this trial succeeds, Dato-DXd would enter direct competition with EV+pembrolizumab in the frontline setting — a head-to-head commercial confrontation between two Daiichi Sankyo ADC programs in different combinations.

TROP2 ADC expansion: Gilead's sacituzumab govitecan

Sacituzumab govitecan (Trodelvy), Gilead's anti-TROP2 ADC approved in breast cancer, is also being evaluated in urothelial carcinoma (NCT03547973). TROP2 is expressed in urothelial carcinoma, providing the mechanistic rationale for expansion. Gilead's program in urothelial positions sacituzumab govitecan as a potential multi-indication ADC, though differentiation from Dato-DXd (also TROP2-directed) will require clear clinical data demonstrating differentiated efficacy or tolerability profiles.

FGFR3-targeted therapy: the molecular subtype opportunity

FGFR3 mutations and fusions are among the most common actionable alterations in urothelial carcinoma, particularly in upper tract urothelial carcinoma (UTUC) and low-grade non-muscle-invasive bladder cancer. Erdafitinib (Balversa) is the approved pan-FGFR inhibitor in this setting, but Tyra Biosciences is developing dabogratinib as a potentially more FGFR3-selective option. Tyra's Phase 2A/B trial specifically enrolls patients with low-grade UTUC — a population with fewer treatment options than muscle-invasive or metastatic disease, and where FGFR3 mutations are particularly prevalent. FGFR3 selectivity may translate to a better therapeutic window with reduced off-target FGFR1/2 toxicity (hyperphosphatemia, retinal pigment epithelial detachment) that limits dose intensity of pan-FGFR inhibitors.

Novel combinations and emerging mechanisms

Alentis Therapeutics is exploring ALE.P03 as monotherapy in selected solid tumors including urothelial cancer — Alentis focuses on anti-fibrotic and tumor microenvironment targets, suggesting a novel mechanism angle in urothelial. Pfizer has filed a Phase 1 study of PF-08046876 in advanced solid tumors including urothelial carcinoma. SystImmune's BL-M07D1 is an HER2-directed ADC in Phase 1 for HER2-expressing solid tumors — HER2 amplification occurs in approximately 6–7% of urothelial cancers and represents a validated but underserved target in the indication.

BCG-naïve NMIBC: the Verity Pharmaceuticals program

Non-muscle-invasive bladder cancer (NMIBC) represents a distinct segment within the urothelial carcinoma landscape. BCG (Bacillus Calmette-Guérin) intravesical therapy is the standard of care for high-risk NMIBC, but supply shortages have plagued the field for over a decade. Verity Pharmaceuticals is conducting a Phase 3 study of Verity-BCG versus comparator in BCG-naïve intermediate and high-risk NMIBC — competing in the supply and quality consistency space rather than with a mechanistically differentiated agent.

What we monitor for urothelial carcinoma trials

Configure a DataLookout profile with these keywords to cover the urothelial carcinoma landscape:

• Broad urothelial: "urothelial carcinoma", "urothelial cancer", "transitional cell carcinoma", "TCC bladder"
• Specific subtypes: "upper tract urothelial", "UTUC", "non-muscle-invasive bladder", "NMIBC", "muscle-invasive bladder cancer", "MIBC"
• Molecular targets: "FGFR3 urothelial", "FGFR3 mutation", "HER2 urothelial", "TROP2 bladder", "Nectin-4"
• Stage/setting: "cisplatin-ineligible urothelial", "platinum-refractory urothelial", "post-EV urothelial"

Phase filter: All phases for comprehensive monitoring. Industry only for competitive intelligence. Status: Recruiting only for active opportunity tracking.

Who uses urothelial carcinoma trial monitoring

Pharma business development teams

Companies with oncology franchises — particularly those holding ADC platforms, checkpoint inhibitor rights, or FGFR-targeted programs — track urothelial trial activity to identify partnership opportunities, competitive threats, and combination strategies. The EV approval has made urothelial carcinoma a high-priority indication for multiple pharma companies expanding their ADC portfolios.

Biotech investors and oncology analysts

The urothelial landscape is crowded with ADC programs, making differentiation analysis essential. Investors need to understand which programs are testing first-line vs. second-line, which targets overlap with EV (Nectin-4) vs. others (TROP2, HER2, FGFR3), and which studies have registrational intent. Tracking trial registrations and design provides early visibility into competitive positioning.

Oncology key opinion leaders and clinical researchers

Academic bladder cancer specialists use trial monitoring to identify studies their patients may qualify for, particularly in FGFR3-mutant upper tract disease where options remain limited. Multiple recruiting Phase 1/2 programs in urothelial carcinoma represent potential enrollment opportunities for patients who have exhausted standard options.

Frequently asked questions

How current is the urothelial cancer trial data?

Our pipeline fetches from ClinicalTrials.gov every morning. Studies posted or updated in the preceding 24 hours appear in that day's digest. ClinicalTrials.gov is updated continuously as sponsors file amendments, add sites, or change trial status.

Can I track both bladder and upper tract urothelial trials separately?

Yes. Configure separate keyword profiles — one for "urothelial carcinoma" broadly, and another with "upper tract urothelial" or "UTUC" or "FGFR3" for programs specifically targeting upper tract disease. Multiple profiles are supported on the Starter ($49/month, 5 profiles) and Pro ($149/month, unlimited profiles) plans.

What is the current standard of care for urothelial carcinoma?

As of 2026, enfortumab vedotin plus pembrolizumab (EV+P, Padcev + Keytruda) is the FDA-approved first-line standard of care for cisplatin-eligible and cisplatin-ineligible metastatic urothelial carcinoma, based on the EV-302/KEYNOTE-A39 trial. Avelumab maintenance (Bavencio) remains an option after platinum-based chemotherapy for non-progressing patients. Active clinical trials are largely testing second-line options, EV-refractory disease, and new ADC challengers in the first-line setting.

How do I track updates to ongoing urothelial trials?

DataLookout alerts include both new trial registrations and updates to existing trials. Configure keywords like "urothelial carcinoma" and you'll receive daily alerts whenever a sponsor updates a protocol, adds enrollment sites, or changes trial status — keeping you current on the status of ongoing programs like the Dato-DXd Phase 2/3.